P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS

V Ryabov,S Mukherjee,I Palme,J Obländer,V Nowak,P Wuchter,C Weiss,J.M Foulks,A Streuer,E Altrock,D Nowak,W.-K Hofmann,A Jawhar,M Göl,F.-C Yang,F Rapp,J.-C Jann,G Ge,L Bolanos,D.T Starczynowski,M Wunderlich,M Jawhar,L Steiner,N Schmitt,N Weimer,A Wein,A Raza,G Metzgeroth,Q Xu,A Darwich,Abdulghani Mohamad Ali

doi:10.1016/j.leukres.2023.107238

P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS

V Ryabov, S Mukherjee + Show 29 more

https://doi.org/10.1016/j.leukres.2023.107238

Copy DOI

Export

Save

Cite

Journal: Leukemia Research

Publication Date: May 1, 2023

Affiliation: University Medical Centre Mannheim, University Hospital Heidelberg, Heidelberg University, Columbia University Irving Medical Center, The University of Texas Health Science Center at San Antonio, Cincinnati Children's Hospital Medical Center

#Presence Of ASXL1mutations #Myelodysplastic Neoplasms #ASXL1 Mutations #Factors Of Response #Augmented Activity

Abstract
Full-Text
Similar Papers

Abstract

Listen

P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Leukemia Research

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS